22840-1681 : Gliocladium Viride .1 g/ml Intradermal; Percutaneous; Subcutaneous Solution


NDC: 22840-1681
Labeler: Greer Laboratories, Inc.
Product Type: Non-standardized Allergenic
Drug Name: Gliocladium Viride
Dosage Form: Intradermal; Percutaneous; Subcutaneous Solution
Application #: BLA101833
Rev. Date: 


NDC Package Codes:

  • 22840-1681-2: 10 ML IN 1 VIAL, MULTI‑DOSE (22840‑1681‑2)
  • 22840-1681-4: 50 ML IN 1 VIAL, MULTI‑DOSE (22840‑1681‑4)

Active Ingredients:

  • Gliocladium Viride

Dosage Strength:

  • .1 g/mL

Pharmaceutical Classes:

  • Non-Standardized Fungal Allergenic Extract [EPC]
  • Increased Histamine Release [PE]
  • Cell-mediated Immunity [PE]
  • Increased IgG Production [PE]
  • Fungal Proteins [CS]
  • Allergens [CS]

Related Products:

Based on records with the same trade name.
  • 22840-1682 Gliocladium Viride .05 g/ml Intradermal; Percutaneous; Subcutaneous Solution by Greer Laboratories, Inc.
  • 22840-1683 Gliocladium Viride .001 g/ml Intradermal; Percutaneous; Subcutaneous Solution by Greer Laboratories, Inc.
  • 22840-1684 Gliocladium Viride 1000 [Pnu]/Ml Intradermal; Percutaneous; Subcutaneous Solution by Greer Laboratories, Inc.
  • 22840-1685 Gliocladium Viride 20000 [Pnu]/Ml Intradermal; Percutaneous; Subcutaneous Solution by Greer Laboratories, Inc.
  • 22840-1686 Gliocladium Viride 40000 [Pnu]/Ml Intradermal; Percutaneous; Subcutaneous Solution by Greer Laboratories, Inc.
  • 22840-5621 Gliocladium Viride .05 g/ml Intradermal; Percutaneous; Subcutaneous Solution by Greer Laboratories, Inc.

NDC QR Code

Scan the QR code below to easily reference this data in the future:

NDC 22840-1681 QR Code

< Prev: 22840-1680Next: 22840-1682 >




Note: The RxChat NDC Database uses publicly available data from the FDA and the U.S. National Library of Medicine (NLM); The NLM is not responsible for the data presented and does not endorse or recommend this or any other product. While we make every effort to ensure that the information presented is accurate, you should assume that all results are unvalidated. To report any errors or inconsistencies please contact us.